BioCentury | Nov 1, 2019
Product Development

Novartis, Merck KGaA see opportunity in select pockets of MS patients

...Ozanimod 0.5mg (n=439) 0.22 p=0.0167 8% (A) Avonex...
...Ozanimod 0.5mg (n=451) 0.241 p=0.0013 8% (A) Avonex...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...by the companies that the net prices of their drugs were lower than SSR’s estimate: Avonex...
BioCentury | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

...consensus estimates of $7.53 and $3.47 billion. MS therapies Tecfidera dimethyl fumarate, Tysabri natalizumab and Avonex...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pomalyst pomalidomide (Imnovid) $1,614.0 $1,473.0 $1,964.0 22% Biogen Inc. (NASDAQ:BIIB) / Eisai Co. Ltd. (Tokyo:4523) Avonex...
BioCentury | Mar 30, 2018
Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

...1 point on the Expanded Disability Status Scale (EDSS) Status: Phase III data Milestone: NA Jennie Walters Avonex...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Genentech Inc. / Roche (SIX:ROG; OTCQX:RHHBY) Perjeta pertuzumab $1,808.7 $1,665.2 $2,220.2 23% Biogen Inc. (NASDAQ:BIIB) Avonex...
BioCentury | Jan 3, 2018
Company News

Allergan among companies unveiling price hikes

...from SunTrust Robinson Humphrey said Biogen Inc. (NASDAQ:BIIB) will increase the price of autoimmune drugs Avonex...
...CRLs for their respective Neulasta biosimilar candidates (see BioCentury Extra, Oct. 10, 2017) . Jaime De Leon ASP0456 Avonex BIIB017 Constella cyclosporine interferon...
BioCentury | Dec 8, 2017
Company News

Biogen agrees to outcomes-based contract for MS portfolio

...Biogen did not respond to inquiries regarding its other pilots. Biogen markets six MS drugs: Avonex...
...Sept. 1 ). Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Prime Therapeutics LLC, Eagan, Minn. Business: Autoimmune Jennie Walters Avonex daclizumab dimethyl...
BioCentury | Dec 1, 2017
Company News

Biogen agrees to outcomes-based contract for MS portfolio

...Biogen did not respond to inquiries regarding its other pilots. Biogen markets six MS drugs: Avonex...
BioCentury | Nov 10, 2017
Clinical News

Novartis reports final Phase III data of Gilenya in pediatric MS

...annualized relapse rate (ARR) over 2 years, the primary endpoint, by 82% vs. once-weekly intramuscular Avonex...
...reducing the number of new or newly enlarged T2 lesions and gadolinium-enhancing T1 lesions vs. Avonex...
...volume loss as measured by MRI vs. Avonex. Furthermore, Gilenya significantly delayed disability progression vs. Avonex...
Items per page:
1 - 10 of 646